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bjectives A novel zotarolimus-eluting coronary stent system (ZoMaxx, Abbott Laboratories, Abbott
ark, Illinois) was compared with a paclitaxel-eluting coronary stent (Taxus Express2) in a randomized
rial of percutaneous intervention for de novo coronary artery stenosis. The primary end point was de-
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ackground The ZoMaxx stent system elutes 10 g/mm zotarolimus using a phosphorylcholine poly-
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ethods Twenty-nine investigative sites in Europe, Australia, and New Zealand enrolled 401 patients,
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esults After 9 months, late lumen loss was signiﬁcantly greater in the ZoMaxx group (in-stent 0.67 
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alue pre-speciﬁed for noninferiority. There were no signiﬁcant differences between ZoMaxx and Taxus-
reated groups with respect to target lesion revascularization (8.0% vs. 4.1%; p  0.14), major adverse
ardiac events (12.6% vs. 9.6%; p  0.43), or stent thrombosis (0.5% in both groups).
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525rug-eluting stents (DES) are intravascular metal scaffolds
hat are coated with antiproliferative agents designed to
reat critical occlusive lesions of the coronary arteries. Stents
luting either sirolimus, paclitaxel, everolimus, or zotaroli-
us have each been shown to effectively inhibit restenosis in
arge-scale clinical trials (1–4). First introduced in 2001,
ES have been widely applied, with over 6 million patients
reated worldwide (5).
See page 533
The clinical trial reported herein was designed to com-
are the novel ZoMaxx zotarolimus-eluting stent (Abbott
aboratories, Abbott Park, Illinois) with the Taxus Ex-
ress2 paclitaxel-eluting stent (Boston Scientific Corpora-
ion, Natick, Massachusetts). The ZoMaxx stent uses the
riMaxx (Abbott Laboratories) stainless steel–tantalum
tent platform to deliver zotarolimus 10 g/mm via a
ell-characterized polymer system based on phosphorylcho-
ine (PC) (6). The objective of this randomized, prospective,
ulticenter trial was to show the safety and efficacy of the
oMaxx stent system as compared with the Taxus Express2
tent system for patients with single de novo lesions in
ative coronary arteries using clinical, angiographic, and
ntravascular ultrasonic methods.
ethods
tudy design and end points. The ZoMaxx I trial was a
andomized, prospective, multicenter clinical trial con-
ucted in accordance with the International Conference on
armonization guidelines–Good Clinical Practices, Decla-
ation of Helsinki, International Organization for Standard-
zation 14155-1, International Organization for Standard-
zation 14155-2, and Ethics Committee requirements. All
atients gave written informed consent for participation.
Patients were considered eligible for inclusion if they
omplained of stable or unstable angina and/or had objec-
ive evidence of myocardial ischemia with angiographically
roven single 50% lesions of 10 to 30 mm in length in
.5- to 3.5-mm native coronary arteries. The major clinical
xclusion criteria were acute myocardial infarction within
he past 72 h, impaired left ventricular function with
jection fraction 30%, or lesions located within the left
ain coronary artery or within 2.0 mm of their ostia.
Secondary end points included device success (achieve-
ent of a final residual in-stent diameter stenosis of 30%
sing the assigned device only), lesion success (30%
esidual stenosis using any percutaneous method), proce-
ure success (lesion success without the occurrence of major
dverse cardiac events [MACE]), angiographic rates of
inary restenosis (50% diameter stenosis) after 9 months,
eointimal hyperplasia volume after 9 months as measured
y intravascular ultrasound (IVUS), and the 9-month inci- cences of ischemia-driven target lesion revascularization
TLR), ischemia-driven target vessel revascularization
TVR), and MACE (composite end point of non–Q-wave
yocardial infarction [MI], Q-wave MI, TVR, and cardiac
eath). The first 250 randomized subjects with IVUS-
ligible lesions were required to have IVUS evaluation
uring the procedure and at 9-month follow-up. A Q-wave
I was defined as the development of new pathological
-waves in 2 or more contiguous leads with post-procedure
reatine kinase (CK) or CK-MB levels elevated above
ormal. Non–Q-wave MI was defined as elevation of
ost-procedure CK levels to 2.0 times normal with
levated CK-MB in the absence of new pathological Q
aves (World Health Organization definition). Acute lu-
inal gain was defined as the difference between the
inimum lumen diameter (MLD) at the completion of the
tenting procedure and at baseline. Data are expressed as the
ean  SD for continuous variables and as frequencies for
ategorical variables (SAS Sta-
istical Analysis Software for
indows, version 8.2, SAS In-
titute Inc., Cary, North Caro-
ina).
tent system. The ZoMaxx
tent was designed to address the
eed for thin strut width and
ow profile, while maintaining
adial strength and adequate vis-
bility on fluoroscopy. The stent
etal is a trilayer composite hav-
ng 2 outer layers of 316L stain-
ess steel and an inner layer of
antalum (Fig. 1) (7). The high
tomic number of the 18-m
nner tantalum layer affords op-
imal radiopacity of the thin
tent struts. The result is a DES with a strut thickness of
nly 0.0029 inches (74 m), an important metric for
inimizing arterial injury and restenosis (8–10).
The ZoMaxx stent elutes 10 g/mm zotarolimus via a
iocompatible PC polymer. Zotarolimus (Fig. 2) was spe-
ifically developed for use on intravascular stents and, like
irolimus, reversibly binds to FKBP-12, the cytosolic recep-
or of FK506 (11,12). Using this mechanism, zotarolimus
nhibits the activation and proliferation of a variety mam-
alian cells at very low concentrations. Its potency for
nhibition of human lymphocytes in vitro has been shown,
s well as the reduction of inflammation in animal models of
rthritis and encephalomyelitis (13). In cultured vascular
ells, zotarolimus inhibits proliferation of canine and human
mooth muscle and endothelial cells with IC50 in the low
anomolar range (11,12,14). It has minimal effects on
Abbreviations
and Acronyms
CK  creatine kinase
DES  drug-eluting stents
IVUS  intravascular
ultrasound
MACE  major adverse
cardiovascular events
MLD  minimum lumen
diameter
PC  phosphorylcholine
TLR  target lesion
revascularization
TVR  target vessel
revascularizationellular migration in vitro, theoretically allowing re-
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526ndothelialization to proceed normally in the presence of
he drug.
The phosphorylcholine polymer drug carrier on the
oMaxx stent, known simply as PC-1036 or PC, is com-
osed of the polymers 2-methacryloyloxyethyl phosphoryl-
holine (MPC), lauryl methacrylate (LMA), hydroxypropyl
ethacrylate (HPMA), and trimethoxysilylpropyl methac-
ylate (TSMA) in the molar ratios of MPC23, LMA47,
PMA25, and TSMA5 (6,15). It has been experimentally
hown to have several properties improving blood–
iomaterial compatibility, including minimal induction of
brinogen absorption, platelet activation, platelet and eryth-
ocyte adherence (15–17), inflammation, and neointimal
yperplasia (6,17–20). Phosphorylcholine has an extensive
ecord of widespread clinical use and safety (6,21–23). It has
lso recently been shown to have considerable potential as a
ehicle for drug elution, especially using highly lipophilic
gents. It is formulated on the ZoMaxx stent to provide a
easured rate of elution so that, in experimental animals,
bout 60% of the total zotarolimus dose is released during
he first week, an additional 20% during the second week,
nd the remaining 20% over the next 2 weeks (24).
reatment protocol. After patient eligibility was established
nd written consent obtained, the lesions were approached
ccording to standard institutional interventional tech-
iques. Patients received oral antiplatelet therapy with
spirin (100 mg/day) and clopidogrel (75 mg/day) starting
efore the procedure and continuing for 6 months. After
ercutaneous access, heparin was administered to maintain
n activated clotting time250 s (or200 s if glycoprotein
Ib/IIIa antagonism was used). Diagnostic coronary angiog-
aphy was performed in matched orthogonal views after
itroglycerin coronary injection (50 to 200 g). After a
Figure 1. The ZoMaxx Stent Platform Consisting of a Trilayer of
Stainless Steel, Tantalum, and Stainless Steel.014-inch wire crossing of the target lesion, randomization1:1 ZoMaxx vs. Taxus) was performed via an interactive
elephone system.
Balloon pre-dilation of the target lesion was mandatory
nd was performed according to standard techniques ensur-
ng that the length of the balloon was no greater than the
ntended stent length. Direct stenting was prohibited in this
tudy. ZoMaxx stents were available in diameters of 2.5, 3.0,
nd 3.5 mm with lengths of 8, 18, 23, 28 mm (2.5-mm
iameter only), and 33 mm (3.0- and 3.5-mm diameters
nly). Taxus stents were available in diameters of 2.5, 3.0,
nd 3.5 mm with lengths of 8, 12, 16, 20, 24, 28 mm (3.0-
nd 3.5-mm diameters only) and 32 mm (3.0- and 3.5-mm
iameters only). Only 1 study stent was to be used per
atient; however, additional stents could be implanted at the
perator’s discretion in the event of edge dissection or
ncomplete coverage.
Intravascular ultrasound images were acquired by motor-
zed pullback at a constant speed of 0.5 mm/s. Baseline,
ost-procedure, and 9-month follow-up coronary cinean-
iographic images (Medis CMS, Leiden, the Netherlands)
nd IVUS tapes (TapeMeasure, Indec Systems, Inc.,
ountain View, California) were analyzed using indepen-
ent core laboratories (Brigham and Women’s Hospital,
oston, Massachusetts, and Stanford University Medical
enter, Palo Alto, California, respectively). Imaging studies
erformed within 284 days (9 months  2 weeks) were
ncluded in the analysis.
onitoring and statistical analysis. The study was moni-
ored by independent contract research organizations (Hes-
erion AG, Allschwil, Switzerland, and Clinimetrics Re-
earch Associates, Inc., San Jose, California) and data were
oordinated and analyzed by the Harvard Clinical Research
nstitute (Boston, Massachusetts). All MACE were re-Figure 2. The Molecular Structure of Zotarolimus
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527iewed and adjudicated by an independent Clinical Events
ommittee whose members were unaware of treatment
llocation. An independent Data and Safety Monitoring
oard periodically reviewed blinded safety data.
The trial was designed to show noninferiority of in-segment
ate loss after 9 months (expected difference in means, Zo-
axx Stent  Taxus Stent  0), with a noninferiority
argin of 0.25 mm and a standard deviation of 0.4 mm. Late
uminal loss was defined as the difference between the MLD
mmediately after stenting and at follow-up. Because late loss
alues 0.6 mm for stented arteries between 2.5 and 3.5 mm
n diameter have little clinical consequence, and the Taxus
tent can be expected to generate 0.23 0.44 mm in-segment
ate loss in this lesion cohort (2), a noninferiority margin of
.25 mm was considered clinically and statistically appropriate.
he trial was 99% powered to detect noninferiority with a
-sided p value of 0.05.
Other treatment group comparisons were performed
sing the 2-sample t test for continuous variables, Fisher
xact test for dichotomous variables, and Cochran-Mantel-
aenszel (Modified Ridit scores) for ordinal variables with
ore than 2 categories. Univariate and multivariate logistic
egression was performed on the binary TVR results to
nderstand the predictive value of several covariates. For the
ultivariate logistic regression, predictors were chosen by
tepwise linear regression using an entry criteria of 0.2 and
stay criteria of 0.1.
esults
our-hundred and one patients were enrolled sequentially
n the study from 29 clinical sites in Europe, Australia, and
ew Zealand (Appendix ). The first patient was enrolled on
eptember 14, 2004, and the final patient was enrolled on
uly 18, 2005. Five patients (4 randomized to ZoMaxx and
randomized to Taxus) were subsequently deregistered
fter randomization and did not receive a study stent (3 were
eemed to be ineligible after randomization, 1 sustained a
omplication before stent insertion, and 1 withdrew consent
efore stent insertion). This left a total of 396 patients for
nalysis (199 ZoMaxx and 197 Taxus).
The clinical and lesional demographics of the 2 patient
ohorts are given in Table 1. The groups were fairly well
atched demographically, as there were similar frequencies
f diabetes (ZoMaxx 22% vs. Taxus 26%) and unstable
ngina (ZoMaxx 26% vs. Taxus 24%). However, there was
tatistically significantly more intervention in the right
oronary artery in the Taxus group versus the ZoMaxx
roup (41% vs. 28%; p  0.008). Furthermore, 8 lesions in
he ZoMaxx group were ostial in location (within 2 mm of
heir origin); there were no ostial lesions in the Taxus group
4.0% vs. 0%; p  0.0007).
Post-procedure metrics are given in Table 2. Lesion and
evice success were 99% for both stents (p  NS). There (ere no differences with respect to post-procedure in-stent
r in-segment MLD, percent diameter stenosis, or acute
ain between the 2 groups.
Angiographic results are given in Table 3. Nine-month
n-segment late lumen loss (primary end point) was 0.43 
.60 mm and 0.25  0.45 mm in the ZoMaxx and Taxus
ngiographic cohorts, respectively; the observed difference
n the means was 0.18 mm. The distributions of in-segment
ate lumen loss in the ZoMaxx and Taxus groups are shown
n Figure 3. Because the upper bound of a 95% confidence
nterval on the difference in the means (0.27 mm) was larger
han the pre-specified noninferiority limit (0.25 mm), the
rimary angiographic end point of noninferiority of in-
egment late lumen loss was not met. Consistent with the
n-segment late loss results, in-segment binary restenosis
as greater in the ZoMaxx group than in the Taxus group
Table 1. Clinical and Lesional Demographics of Patients Enrolled in the
ZoMaxx I Trial
ZoMaxx
(n  199)
Taxus
(n  197) p Value
Age (yrs) 63 10 63 11 NS
Male gender 75% 77% NS
Diabetes 22% 26% NS
IDDM 8.0% 8.6% NS
Unstable angina 26% 24% NS
Hypercholesterolemia 78% 72% NS
Hypertension 69% 67% NS
Family history of premature CAD 39% 34% NS
Current smoker 24% 19% NS
Prior MI 29% 29% NS
Prior PCI 20% 25% NS
Prior CABG 4.5% 1.0% NS
LVEF 65% 12% 65% 11% NS
Vessel location 0.025
LAD 48% 40%
LCX 24% 19%
RCA 28% 41% *
Lesion location 0.031
Ostial 4.0% 0.0% †
Proximal 39% 41%
Mid 51% 51%
Distal 6.0% 8.6%
Lesion length (mm) 14.9 5.7 14.6 5.5 NS
RVD (mm) 2.79 0.43 2.81 0.46 NS
Total stent length (mm) 21.3 5.9 20.8 5.7 NS
Stent-to-lesion ratio 1.6 0.6 1.6 0.6 NS
Stents per patient 1.1 0.4 1.1 0.3 NS
*RCA vs. other locations, p 0.008. †Ostial vs. other locations, p 0.007.
CABG  coronary artery bypass grafting; CAD  coronary artery disease; IDDM  insulin-
dependent diabetes mellitus; LAD left anterior descending coronary artery; LCX left circum-
flex coronary artery; LVEF  left ventricular ejection fraction; MI  myocardial infarction; PCI 
percutaneous coronary intervention; RCA right coronary artery; RVD reference vessel diameter.16.5% vs. 6.9%; p  0.007).
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528Similarly, in-stent late lumen loss was found to be
tatistically significantly greater after ZoMaxx stenting as
ompared with Taxus stenting (0.67  0.57 mm vs. 0.45 
. 48 mm; p  0.0001), resulting in a higher frequency of
n-stent restenosis in the ZoMaxx group (12.9% vs. 5.7%;
 0.025). Even using nonparametric analysis, more
ppropriate for non-normal distributions such as late loss
fter implantation of DES (25,26), the difference in the
edians remained statistically significant (median in-stent
ate loss ZoMaxx 0.58 mm vs. Taxus 0.41 mm; p  0.05
sing the Kruskal-Wallis test).
Clinical results at 9 months encompassing all follow-up
ngiography performed up to 284 days are given in Table 4;
-month clinical follow-up was available in 96% of patients
382 of 396). There were no significant differences between
reatment groups for any clinical end point. The rate of
LR was nearly double in the ZoMaxx group as compared
ith the Taxus group (8.0% vs. 4.1%), although the differ-
nce did not reach statistical significance (p  NS). There
ere no differences in the incidence of stent thrombosis
hether protocol-defined (0.5% in both groups) or retro-
Table 2. Post-Procedural Results in the ZoMaxx I Tri
ZoMaxx (n  19
Lesion success 198 (99%)
Device success 197 (99%)
Procedure success 188 (95%)
In-stent (n  170)
MLD (mm) 2.71 0.39
Diameter stenosis (%) 4.6 7.9
Acute gain (mm) 1.90 0.41
In-segment (n  170)
MLD (mm) 2.29 0.47
Diameter stenosis (%) 20 9.7
Acute gain (mm) 1.49 0.45
MLDminimum lumen diameter.
Table 3. 9-Month Angiographic Results in the ZoMaxx I Trial
Angiographic Results
ZoMaxx
(n  170)
Taxus
(n  175) p Value
In-stent
MLD (mm) 2.03 0.63 2.27 0.58 0.001
Diameter stenosis (%) 27 21 19 17 0.001
Late loss (mm) 0.67 0.57 0.45 0.48 0.001
Restenosis (%) 12.9 5.7 0.025
In-segment
MLD (mm) 1.86 0.59 2.04 0.55 0.004
Diameter stenosis (%) 34 19 28 14 0.001
Late loss (mm) 0.4 0.60 0.25 0.45 0.003
Restenosis (%) 16.5 6.9 0.007aMLDminimum lumen diameter.pectively applying the definitions suggested by the Aca-
emic Research Consortium (27) (1.0% in both groups).
The IVUS results are given in Table 5. Neointimal
olume obstruction by IVUS was statistically significantly
reater after ZoMaxx stenting (14.6  7.9% vs. 11.2  9.6
; p 0.018). The incidence of late acquired malapposition
as slightly less after ZoMaxx stenting, although the
ifference did not reach statistical significance (0% vs. 3%;
 NS).
To evaluate the possible predictive value of covariates in
he ZoMaxx I study, both univariate and multivariable
ogistic regression analyses were performed on the entire
atient cohort to identify significant risk factors for the need
or follow-up TVR. The results, shown in Table 6, identify
nly ostial lesion location (p  0.002) and the presence of
iabetes (p  0.003) as statistically significant predictors of
he need for TVR after 9 months.
iscussion
lthough a variety of antiproliferative agents have been
uggested as putative inhibitors of stent-induced restenosis,
nly sirolimus (1), paclitaxel (2), everolimus (3), and zo-
arolimus (28) have been proven safe and effective in
arge-scale, multicenter, randomized clinical trials. One
ompound, zotarolimus (formerly known as ABT-578,
bbott Laboratories) (Fig. 2), has been specifically devel-
ped for use in DES having no other systemic formulation
r indication. Intravascular stents that elute zotarolimus
ave been shown to be effective in inhibiting in-stent
estenosis both in experimental animal models (29) and in
atients undergoing percutaneous coronary intervention
4,28).
To date, 4 zotarolimus-eluting devices have been tested
linically: the Prefer (Abbott Laboratories) (30), Endeavor
Medtronic, Minneapolis, Minnesota), (4) ZoMaxx (31),
Taxus (n  197) p Value
195 (99%) NS
194 (99%) NS
189 (96%) NS
(n  175)
2.72 0.43 NS
4.4 8.5 NS
1.96 0.49 NS
(n  175)
2.29 0.49 NS
20 9.5 NS
1.53 0.51 NSal
9)nd Resolute (Medtronic) (32) stents. The most extensively
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529tudied is the Endeavor stent, which also contains 10 g/ml
otarolimus in a PC-based formulation that, in experimen-
al animals, elutes approximately 95% of its drug load over
bout 15 days (4). The Endeavor II pivotal trial compared
he Endeavor stent to the bare metal Driver stent in 1,200
atients, and the results showed highly statistically signifi-
ant reductions in late lumen loss (in-stent 1.03 0.58 mm
s. 0.61  0.46 mm; p  0.0001), angiographic binary
estenosis (in-stent 33.5% vs. 9.4%; p  0.0001), target
Figure 3. Distribution of In-Segment Late Loss in the Taxus and ZoMaxx C
Table 4. 9-Month Clinical Results in the ZoMaxx I Tr
284 Days)
ZoMaxx
Q-wave MI 1.0
Non–Q-wave MI 4.5
TVR (ischemia-driven) 8.5
Cardiac death 0.0
Total MACE† 12
TLR 8.0
Non–TL TVR 2.5
Target vessel failure 12
All death 1.5
Total stent thrombosis (protocol-deﬁned) 0.5
Acute stent thrombosis (24 h) 0.0
Subacute stent thrombosis (1–30 days) 0.5
Late stent thrombosis (30 days) 0.0
Total stent thrombosis (ARC-deﬁned) 1.0
Acute stent thrombosis (24 h) 0.5
Subacute stent thrombosis (1–30 days) 0.0
Late stent thrombosis (30 days) 0.5
*Includes 3 instances of TLR in ostial lesions. †MACE is a composite h
‡Three noncardiac deaths include 1 patient with acute renal and mult
212, and 1 patient with intracerebral hemorrhage at day 274.
ARCAcademic ResearchConsortium (27); adefinite; bprobab target lesion revascularization; TVR target vessel revascularization; otheressel failure (15.1% vs. 7.9%; p  0.0001) and MACE
14.4% vs. 7.3%; p 0.0001) (28). Based on these and other
linical trial results (4,33,34), the Endeavor stent is now
pproved for clinical use worldwide.
The ZoMaxx stent was first tested clinically in the
oMaxx IVUS trial, which enrolled 40 patients with symp-
omatic ischemic coronary occlusive disease at the Instituto
ante Pazzanese de Cardiologia in Saõ Paulo, Brazil (31).
he lesion, procedure, and device-deployment success rates
of the ZoMaxx I Trial
cludes All Follow-Up Angiograms Performed Through
199) Taxus (n  197) p Value
0.5% NS
4.1% NS
6.6% NS
0.0% NS
9.6% NS
4.1% NS
3.0% NS
9.6% NS
0.0% NS
0.5% (1) NS
0.0% NS
0.5% (1) NS
0.0% NS
1.0% (2) NS
0.5% (1)b NS
0.5% (1)a NS
0.0% NS
cal end point of Q-wave MI, non–Q-wave MI, TVR, and cardiac death.
failure at day 91, 1 patient with neuroendocrine malignancy at day
ossible;MACEmajor adverse cardiac events; TL target lesion; TLRial (In
(n 
%
%
%*
%
.6%
%*
%
.6%
%‡
% (1)
%
% (1)
%
% (2)
% (1)a
%
% (1)c
ierarchi
iorgan
le; cpabbreviations as in Table 1.
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530ere all 100% (40 of 40), and there was no MACE during
he 4-month study. Follow-up angiography at 4 months
howed in-stent and in-segment late lumen losses of 0.20
.35 mm and 0.17  0.35 mm, respectively, with IVUS
xaminations showing a mean of 6.5  6.2% neointimal
olume obstruction. There were no instances of late ac-
uired stent incomplete apposition or stent thrombosis. In
omparison with a similar clinical trial using the nondrug
riMaxx stent studied angiographically at 6 months, the
oMaxx stent significantly reduced in-stent restenosis from
5% to 2.7% (35).
These initial observations were extended through the
oMaxx I clinical trial reported herein. The ZoMaxx I trial
as designed to study a larger and more complex patient
ohort with longer duration of follow-up in multinational
eographies and to concurrently compare the outcome of
oMaxx stent implantation with patients treated with the
axus paclitaxel-eluting stent.
The ZoMaxx and Taxus patient groups in the ZoMaxx I
rial were generally well-matched in both clinical and lesion
haracteristics. The exception was the preponderance of
stial lesions within the ZoMaxx cohort (n  8) as
Table 5. 9-Month IVUS Results in the ZoMaxx I Trial
ZoMaxx
(n  114)
Taxus
(n  120)
p
Value
Stent volume (mm3) 155 62 143 58 NS
Lumen volume (mm3) 132 54 127 55 NS
Neointimal volume (mm3) 23 16 16 15 0.007
Neointimal volume obstruction (%) 14.6 7.9 11.2 9.6 0.018
Post-procedure SIA 19 (20%) 19 (19%) NS
Persistent SIA 9 (9.6%) 10 (9.9%) NS
Resolved SIA 10 (10.6%) 9 (8.9%) NS
New (late-acquired) SIA 0 (0%) 3 (3.0%) NS
IVUS intravascular ultrasound; SIA stent incomplete apposition.
Table 6. Univariate and Multivariate Logistic Regress
Predictor Coefficie
Univariate
Diabetes 1.34
Lesion location (ostial vs. others) 2.11
Reference vessel diameter 1.06
Degree of calciﬁcation (mod/severe) 0.67
Lesion grade (C vs. all others) 0.51
ZoMaxx vs. Taxus 0.36
Vessel location (LAD vs. others) 0.11
Pre-procedure MLD 0.12
Lesion length 0.00
Multivariate
Lesion location (ostial vs. others) 2.77
Diabetes 1.61LAD left anterior descending coronary artery; MLDminimum lumen diamompared with the Taxus cohort (n  0). This occurrence
as random and was uncovered as a result of retrospective
ore laboratory analysis of baseline angiograms, wherein
esions believed to be acceptable candidates for entry into
he study were subsequently found to be within 2 mm of the
rtery’s origin. It is known that percutaneous treatment of
stial occlusive lesions carries a substantially higher risk of
estenosis (36–39), TVR (37), and 1-year mortality (40),
nd this is why patients with lesions that are located near
ne of the coronary ostia have been specifically excluded
rom pivotal clinical trials of DES (1,2,28). Indeed, the
resence of an ostial lesion was the most significant multi-
ariate predictor of TVR in the 386-patient cohort (p 
.002), even slightly stronger than the presence of diabetes
ellitus (p  0.003).
The inclusion of patients with ostial lesions in the
oMaxx group notwithstanding, there were no differences
etween the ZoMaxx and Taxus stent in device deployment
r safety as shown by the high rates of device success (99%
n both groups), a low stent thrombosis rate, and the
bsence of late stent thrombosis. There were no significant
ifferences between treatment groups for any clinical metric
hat was evaluated (Table 4), although the study was not
pecifically powered to detect differences in infrequent
vents.
The most important finding in this clinical study was the
tatistically significant difference in late lumen loss between
he 2 angiographic cohorts. The frequencies of both angio-
raphic (87%) and IVUS (59%) follow-up are among the
ighest reported in any clinical trial of DES. After 9
onths, patients treated with the ZoMaxx stent showed a
ean in-segment late lumen loss of 0.43  0.60 mm,
hereas patients treated with the Taxus stent showed only
.25  0.45 mm of luminal loss (p  0.001). Because the
pper bound of a 95% confidence interval on the difference
nalysis of Predictors of TVR in the ZoMaxx I Trial
SE Odds Ratio p Value
0.50 3.8 0.007
0.86 8.3 0.014
0.59 0.35 0.072
0.65 0.51 0.30
0.58 0.60 0.39
0.50 1.44 0.47
0.50 0.90 0.83
0.78 1.13 0.88
0.04 1.0 0.96
0.91 16.0 0.002
0.54 5.0 0.003ion A
nt
2eter; TVR target vessel revascularization.
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531etween treatment groups for in-segment late loss was 0.27
m (larger than the pre-specified 0.25 mm), the primary
ngiographic end point of noninferiority of in-segment late
umen loss was not met.
Given the differences in late lumen loss and the well-
escribed curvilinear relationship of late loss to restenosis
25), it is not surprising that the ZoMaxx group was found
o have statistically significantly higher rates of in-stent
estenosis (12.9% vs. 5.7%; p  0.025), as well as a trend
oward increased ischemia-driven TLR as compared with
axus (8.0% vs. 4.1%; p  NS). The specific mechanisms
nderlying these findings are speculative. The 2 stent
ystems differ in all critical design elements, including their
tent platforms, drugs, pharmacological mechanisms of
ction, polymers, and formulations. The nondrug bare metal
tent platforms seem to yield roughly comparable clinical
nd angiographic results, bearing in mind the relatively
mall patient cohorts subjected to rigorous angiographic
ollow-up (2,7,35). Both drugs have been shown to effec-
ively inhibit mammalian cell proliferation in vitro and in
nimal models (29,41), and both have yielded variable
linical and angiographic results depending on their formu-
ations, intervals of angiographic follow-up, and specific
opulations under study (range of in-stent late loss for
aclitaxel-eluting stents: 0.30 to 0.81 mm [2,42–45];
otarolimus-eluting stents: 0.12 to 0.67 mm [28,32,33,46]).
t is noteworthy that the 9-month in-stent late lumen loss of
atients treated with the ZoMaxx stent in this study (0.67
.57 mm) is strikingly similar to 8-month late lumen loss of
atients treated with the Endeavor stent in each of En-
eavor II (0.62 0.46 mm) (28), Endeavor III (0.60 0.48
m) (33) and Endeavor IV (0.67  0.49 mm) clinical trials
47). Thus, the prolonged release rate of ZoMaxx (24) as
ompared with Endeavor showed in nonconcurrent animal
esting (4,24) had no apparent effect on results in humans.
nterestingly, a zotarolimus-eluting stent using a different
olymer formulation and having an even longer elution rate
han ZoMaxx has recently been developed (Endeavor Res-
lute, Medtronic). Preliminary angiographic results in 30
atients suggest enhanced inhibition of neointimal hyper-
lasia using this formulation with a mean in-stent late loss
f 0.12  0.26 mm after 4 months (32). It can only be
oncluded that the efficacy of a given DES continues to be
ifficult to predict empirically and that long-term compar-
tive clinical testing of each new formulation is required
efore its widespread application.
onclusions
he ZoMaxx Coronary Stent can be safely implanted for
he treatment of de novo coronary artery stenosis, as
videnced by the high rate of device implantation success
99%) and the low rates of subacute (0.5%) and late (0%)
tent thrombosis. After 9 months, the ZoMaxx stenthowed less neointimal inhibition than the Taxus stent, as
emonstrated by higher in-stent late loss and restenosis by
CA and neointimal volume obstruction by IVUS.
eprint requests and correspondence: Dr. Lewis B. Schwartz,
bbott Laboratories, 200 Abbott Park Road, AP52-2, Abbott Park,
llinois 60064-6215. E-mail: lewis.schwartz@abbott.com.
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